Surrozen, Inc./DE Sale of Stock, Consideration Received on Transaction
Surrozen, Inc./DE (SRZN) reported Sale of Stock, Consideration Received on Transaction of $50.00 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2022-08-11
- Surrozen, Inc./DE sale of stock, consideration received on transaction for the quarter ending 2022-06-30 was $0.00.
- Surrozen, Inc./DE sale of stock, consideration received on transaction for the quarter ending 2022-03-31 was $50.00M.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month |
|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $50.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $50.00M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |